Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN FE 1/20 vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy in women who elect to use an oral contraceptive
Prevention of pregnancy
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Ethinyl estradiol is metabolized primarily via CYP3A4, with sulfation and glucuronidation. Norethindrone is reduced and conjugated, primarily via CYP3A4 and other CYP450 enzymes.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Ethinyl estradiol: 97-98% (albumin, SHBG); norethindrone: 80-85% (albumin, SHBG)
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
Ethinyl estradiol: 2.5-5 L/kg; norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Oral: ~40% for ethinyl estradiol (first-pass metabolism); ~64% for norethindrone (range 50-75%)
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 m L/min) may require monitoring due to potential fluid retention; use lowest effective dose.
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Contraindicated in Child-Pugh class C cirrhosis. For Child-Pugh class B, use with caution and only if benefits outweigh risks; consider alternative methods of contraception. Child-Pugh class A: no adjustment necessary.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Approved for post-menarcheal adolescents. Same dosing as adults: one active tablet daily for 21 days, then placebo for 7 days. Weight-based adjustments not required.
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
Not indicated for postmenopausal women. No specific geriatric dose adjustments, but consider increased risk of thrombotic events and manage cardiovascular risk factors.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. The risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women >35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders: Risk of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction.,Hepatic disease: Discontinue if jaundice or cholestasis develops.,Hypertension: Monitor blood pressure; may cause new-onset or worsening hypertension.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate metabolism: May impair glucose tolerance.,Hypertriglyceridemia: May cause pancreatitis if elevated.,Uterine bleeding: Discontinue if unexplained amenorrhea or irregular bleeding persists.,Ocular disorders: Retinal thrombosis; discontinue if sudden partial or complete vision loss.,Depression: May recur or worsen.,Toxic shock syndrome: Associated with use of vaginal rings, but not specifically with this pill.
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Benign or malignant liver tumors (current or history),Active liver disease (e.g., acute hepatitis, decompensated cirrhosis),Hypersensitivity to any component of the product
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
No significant food interactions. However, grapefruit juice may slightly increase ethinyl estradiol levels; avoid large amounts. The ferrous fumarate in placebo pills may cause gastrointestinal upset; take with food if needed.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
Pregnancy category X. Use contraindicated in pregnancy due to known teratogenicity. First-trimester exposure associated with cardiovascular defects and limb reduction defects. Second and third trimesters: no increased risk of malformations but potential for adverse effects from progestational agents and estrogen. Risk of fetal genital abnormalities with prolonged exposure.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Contraindicated in breastfeeding. Small amounts of estrogen and progestin (norethindrone) pass into breast milk. M/P ratio: not established for this combination. May reduce milk production and quality. Use alternative contraception if breastfeeding.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
Contraindicated in pregnancy; no dose adjustments recommended as use is prohibited. No pharmacokinetic studies during pregnancy due to contraindication.
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
LARIN FE 1/20 is a combination oral contraceptive containing norethindrone acetate (1 mg) and ethinyl estradiol (20 mcg). It uses a 24/4 regimen with 24 active pills and 4 ferrous fumarate placebo pills. The iron supplements in the placebo pills help reduce the risk of iron deficiency anemia. Advise patients that spotting or breakthrough bleeding is common in the first few cycles. Monitor for hypertension, migraines, and thrombotic events. Smoking increases cardiovascular risk, especially in women over 35. LARIN FE 1/20 may decrease milk production in breastfeeding women.
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take one pill daily at the same time each day. Swallow the pill whole; do not crush or chew.,Start the pack on the first Sunday after your period starts (unless instructed otherwise).,Use backup contraception (like condoms) for the first 7 days if you start taking the pill for the first time.,If you miss a pill, refer to the package insert for instructions. Missing pills increases pregnancy risk.,Common side effects include nausea, breast tenderness, and breakthrough bleeding. These often improve after a few months.,Contact your healthcare provider if you experience severe abdominal pain, chest pain, sudden shortness of breath, severe headaches, vision changes, or leg pain/swelling (possible blood clots).,Talk to your doctor before starting if you smoke, are over 35, have high blood pressure, migraines with aura, or a history of blood clots.,The iron pills (brown tablets) are not active birth control; they are taken during the fourth week to help prevent anemia.,Do not stop taking the pill without consulting your doctor.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN FE 1/20 vs LARIN 1.5/30, answered by our medical review team.
LARIN FE 1/20 is a Combination Oral Contraceptive that works by LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN FE 1/20 and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN FE 1/20 is: One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN FE 1/20 and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN FE 1/20 is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy due to known teratogenicity. First-trimester exposure associated with cardiovascular defects and limb reduction defects. Seco. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.